FDA obesity public meeting
This article was originally published in The Tan Sheet
Executive Summary
The agency will discuss the available evidence that it "can look to in order to guide rational, effective public efforts to prevent and treat obesity by behavioral or medical interventions, or combinations of both" at an upcoming open meeting, according to an Oct. 7 1notice. The meeting, which is being organized by FDA's Obesity Working Group, will be held Oct. 23 at NIH in Bethesda, Md. Commissioner Mark McClellan, MD/PhD, has frequently talked about the need for more anti-obesity medications...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.